InnoCare Announces Approval of Orelabrutinib in Australia

BEIJING, May 27, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that orelabrutinib (HIBRUKA®) has been